Press Releases CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-18 pm EDT			5-day change	1st Jan Change
5.390 ^USD	-0.19%		-1.28%	+58.06%

Jul. 14	CUREVAC : Pipeline pruning’s nasty effect
Jul. 01	CureVac N.V. - Shareholder/Analyst Call

Press Releases

BioNTech Announces Transaction To Acquire CureVac	Jul. 01	AQ
CureVac N : Pressemitteilung	Jun. 24	PU
CureVac Announces Voting Results of General Meeting	Jun. 24	EQ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders	Jun. 12	PR
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders	Jun. 12	BU
CureVac N : Proxy Card AGM 2025	May. 23	PU
CureVac N : Dutch Statutory Board Report and Financial Statements of CureVac N.V. 2024	May. 23	PU
CureVac N : Proxycard AGM 2025	May. 23	PU
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates	May. 20	EQ
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE	May. 15	EQ
CureVac N : Fourth Quarter and Full-Year 2024 Financial Results and Business Update – Conference Call & Webcast Transcript	Apr. 22	PU
CureVac N : Fourth Quarter and Full-Year 2024 Financial Results and Business Update – Conference Call & Webcast Presentation	Apr. 10	PU
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update	Apr. 10	EQ
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025	Apr. 08	EQ
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer	Apr. 07	EQ
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE	Mar. 27	EQ
CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators	Feb. 18	EQ
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Form 6 K	Nov. 12	PU
CureVac N : Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Form 6 K	Nov. 12	PU
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update	Nov. 12	EQ
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024	Nov. 07	EQ
CureVac N : Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer Form 6 K	Nov. 04	PU
CureVac N : to Present at the 12th International mRNA Health Conference Form 6 K	Nov. 04	PU
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer	Nov. 04	EQ
CureVac to Present at the 12th International mRNA Health Conference	Nov. 04	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : Pipeline pruning’s nasty effect

July 14, 2025 at 03:52 am EDT